Ethical considerations for the clinical oncologist in an era of oncology drug shortages

Oncologist. 2014 Feb;19(2):186-92. doi: 10.1634/theoncologist.2013-0301. Epub 2014 Jan 21.

Abstract

Shortages of injectable drugs affect many cancer patients and providers in the U.S. today. Scholars and policymakers have recently begun to devote increased attention to these issues, but only a few tangible resources exist to guide clinical oncologists in developing strategies for dealing with drug shortages on a recurring basis. This article discusses existing information from the scholarly literature, policy analyses, and other relevant sources and seeks to provide practical ethical guidance to the broad audience of oncology professionals who are increasingly confronted with such cases in their practice. We begin by providing a brief overview of the history, causes, and regulatory context of oncology drug shortages in the U.S., followed by a discussion of ethical frameworks that have been proposed in this setting. We conclude with practical recommendations for ethical professional behavior in these increasingly common and challenging situations.

Keywords: Drug; Ethics; Oncology; Policy; Recommendations; Shortage.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / economics
  • Antineoplastic Agents / supply & distribution*
  • Child
  • Drug Costs
  • Female
  • Health Care Rationing / ethics*
  • Health Care Rationing / methods
  • Humans
  • Medical Oncology / ethics*
  • Middle Aged
  • Neoplasms / drug therapy*
  • Physicians
  • United States

Substances

  • Antineoplastic Agents